Patents Assigned to STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC INSTITUTE & CO.
-
Patent number: 9596834Abstract: Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated.Type: GrantFiled: February 27, 2014Date of Patent: March 21, 2017Assignee: Stelic Institute of Regenerative Medicine, Stelic Institute & Co.Inventors: Hiroyuki Yoneyama, Masato Fujii
-
Publication number: 20170067058Abstract: As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).Type: ApplicationFiled: July 21, 2016Publication date: March 9, 2017Applicant: STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC INSTITUTE & CO.Inventors: Hiroyuki YONEYAMA, Jun KOYAMA, Masato FUJII
-
Publication number: 20160355818Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.Type: ApplicationFiled: August 19, 2016Publication date: December 8, 2016Applicants: Stelic Institute of Regenerative Medicine, Stelic Institute & Co., Niigata UniversityInventors: HIROYUKI YONEYAMA, Kenji SUZUKI
-
Publication number: 20150290238Abstract: As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).Type: ApplicationFiled: May 5, 2015Publication date: October 15, 2015Applicant: Stelic Institute of Regenerative Medicine, Stelic Institute & Co.Inventors: Hiroyuki YONEYAMA, Jun KOYAMA, Masato FUJII
-
Publication number: 20140178306Abstract: Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated.Type: ApplicationFiled: February 27, 2014Publication date: June 26, 2014Applicant: STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC INSTITUTE & CO.Inventors: HIROYUKI YONEYAMA, MASATO FUJII
-
Publication number: 20140135379Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Applicants: NIIGATA UNIVERSITY, Stelic Institute of Regenerative Medicine, Stelic Institute & CO.Inventors: Hiroyuki YONEYAMA, Kenji SUZUKI
-
Publication number: 20140128452Abstract: As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).Type: ApplicationFiled: November 8, 2013Publication date: May 8, 2014Applicant: STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC INSTITUTE & CO.Inventors: Hiroyuki YONEYAMA, Jun KOYAMA, Masato FUJII